Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Transitional Cell 25 Urinary Bladder Neoplasms 23 Ureteral Neoplasms 8 Urologic Neoplasms 4 Urethral Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Neoplasms 3 Neoplasm Metastasis 3 Urogenital Neoplasms 2 Muscle Invasive Bladder Urothelial Carcinoma 2 Metastatic Urothelial Cancer 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Advanced Bladder Cancer 2 Urothelial Cancer 1 Urologic Diseases 1 Urogenital Diseases 1 Urinary Bladder Diseases 1 Urachal adenocarcinoma 1 Triple Negative Breast Neoplasms 1 Salivary Gland Neoplasms 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Peripheral Nervous System Diseases 1 Penile Squamous Cell Carcinoma (PSCC) 1 Penile Neoplasms 1 Pancreatic Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms by Site 1 Muscle-invasive Bladder Cancer 1

Interventions

Injections 26 toripalimab 17 pembrolizumab 17 tislelizumab 12 Gemcitabine 8 Cisplatin 7 spartalizumab 6 atezolizumab 6 Irinotecan 6 Carboplatin 6 Paclitaxel 5 Oxaliplatin 5 Nivolumab 5 Leucovorin 5 Fluorouracil 5 camrelizumab 4 Pemetrexed 4 Docetaxel 4 Cetuximab 4 Capecitabine 4 trastuzumab deruxtecan 3 sintilimab 3 olaparib 3 lenvatinib 3 cediranib 3 PM 01183 3 Drug Therapy 3 Cyclophosphamide 3 Bevacizumab 3 Albumin-Bound Paclitaxel 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Solid Tumor × enfortumab vedotin × Clear all

NCT07157956 2025-09-05

CVL006-T1002

Convalife (Shanghai) Co., Ltd.

Phase 1/2 Not yet recruiting

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡